Neonatal Hypoxia/Ischemia Is Associated With Decreased Inflammatory Mediators After Erythropoietin Administration

Background and Purpose— Erythropoietin (EPO), a hematopoietic growth factor, has been shown to be neuroprotective when administered as either a pretreatment or posttreatment. This study tested the hypothesis that one of the mechanisms of protection afforded by posttreatment with recombinant human EPO (rh-EPO) is an anti-inflammatory effect via inhibition of interleukin (IL)-1&bgr;. Methods— Seven-day-old rat pups were subjected to unilateral carotid artery ligation followed by 90 minutes of hypoxia (8% O2 at 37°C). Pups were divided into the following groups: control, hypoxia/ischemia, and hypoxia/ischemia plus rh-EPO. In the rh-EPO–treated pups, rh-EPO (5 U/g body weight IP) was administered starting 24 hours after the insult and then for 2 additional days. Samples were collected at 3, 7, 14, and 21 days after the insult. IL-1&bgr; mRNA and protein levels were determined by quantitative real-time reverse transcription–polymerase chain reaction and ELISA. Tumor necrosis factor (TNF)-&agr; mRNA levels were determined by colorimetric microplate assay. Results— rhEPO attenuated brain injury, as assessed by brain weight, and attenuated both the hypoxia/ischemia–induced increases in IL-1&bgr; mRNA and protein levels. TNF-&agr; mRNA levels did not increase at 3 to 14 days after the hypoxic/ischemic insult. Conclusions— Administration of exogenous rh-EPO starting 24 hours after a hypoxic/ischemic insult is neuroprotective in the neonatal rat. This neuroprotective activity prevented the secondary, delayed rise in IL-1&bgr; and attenuated the infiltration of leukocytes into the ipsilateral hemisphere.

[1]  K. Maiese,et al.  Erythropoietin in the brain: can the promise to protect be fulfilled? , 2004, Trends in pharmacological sciences.

[2]  H. Ozkan,et al.  Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia–ischemia in rats , 2004, Behavioural Brain Research.

[3]  P. Ghezzi,et al.  Erythropoietin as an antiapoptotic, tissue-protective cytokine , 2004, Cell Death and Differentiation.

[4]  Ying Wang,et al.  Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats , 2004, Stroke.

[5]  A. Cerami,et al.  Erythropoietin as a Tissue-Protective Cytokine in Brain Injury: What Do We Know and Where Do We Go? , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[6]  John H. Zhang,et al.  Mechanisms of Erythropoietin-induced Brain Protection in Neonatal Hypoxia-Ischemia Rat Model , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  P. Ghezzi,et al.  Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis , 2003, The Journal of experimental medicine.

[8]  Ç. Ulukuş,et al.  Neuroprotective Effect of Erythropoietin on Hypoxic-Ischemic Brain Injury in Neonatal Rats , 2003, Neonatology.

[9]  J. Barks,et al.  Pathogenesis of hypoxic-ischemic cerebral injury in the term infant: current concepts. , 2002, Clinics in perinatology.

[10]  P. Ghezzi,et al.  Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis , 2002, Brain Research.

[11]  O. Ramilo,et al.  Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. , 2002, Pediatrics.

[12]  John H. Zhang,et al.  Hyperbaric oxygenation prevented brain injury induced by hypoxia–ischemia in a neonatal rat model , 2002, Brain Research.

[13]  K. Blomgren,et al.  Interleukin-18 Involvement in Hypoxic–Ischemic Brain Injury , 2002, The Journal of Neuroscience.

[14]  R. Hata,et al.  Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up‐regulating Bcl‐xL expression , 2002, Journal of neuroscience research.

[15]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Greenberg,et al.  Erythropoietin protects cultured cortical neurons, but not astroglia, from hypoxia and AMPA toxicity , 2000, Neuroscience Letters.

[18]  G. Meloni,et al.  Chronic myeloid leukemia in first chronic phase not responding to α-interferon: outcome and prognostic factors after autologous transplantation , 1999, Bone Marrow Transplantation.

[19]  K. Blomgren,et al.  Chemokine and Inflammatory Cell Response to Hypoxia-Ischemia in Immature Rats , 1999, Pediatric Research.

[20]  A. Shah,et al.  Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. , 1998, The Journal of clinical investigation.

[21]  R. Romero,et al.  Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1β, and tumor necrosis factor-α), neonatal brain white matter lesions, and cerebral palsy , 1997 .

[22]  E. Morishita,et al.  Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death , 1996, Neuroscience.

[23]  M. Blennow,et al.  Enhanced Expression of Interleukin (IL)-1 and IL-6 Messenger RNA and Bioactive Protein after Hypoxia-Ischemia in Neonatal Rats , 1996, Pediatric Research.

[24]  J. Szaflarski,et al.  Cerebral hypoxia-ischemia stimulates cytokine gene expression in perinatal rats. , 1995, Stroke.

[25]  N. Chinookoswong,et al.  The Interleukin-1 Receptor Antagonist (rhIL-1ra) Protects against Cerebral Infarction in a Rat Model of Hypoxia-Ischemia , 1994, Experimental Neurology.

[26]  Thomas K. Hunt,et al.  ON THE TREATMENT OF , 1846 .